MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

Search

Clearside Biomedical Inc

Closed

0.83 2.47

Overview

Share price change

24h

Current

Min

0.81

Max

0.86

Key metrics

By Trading Economics

Income

-917K

-8.2M

Sales

2M

2.3M

Profit margin

-352.918

Employees

32

EBITDA

-102K

-4.8M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+550.6% upside

Dividends

By Dow Jones

Next Earnings

11 Aug 2025

Market Stats

By TradingEconomics

Market Cap

-53K

69M

Previous open

-1.64

Previous close

0.83

Technical Score

By Trading Central

Confidence

Neutral Evidence

Clearside Biomedical Inc Chart

Past performance is not a reliable indicator of future results.

Related News

16 Jul 2025, 23:56 UTC

Acquisitions, Mergers, Takeovers

Alimentation Couche-Tard Ends Bid to Buy Seven & I Holdings -- 2nd Update

16 Jul 2025, 23:43 UTC

Acquisitions, Mergers, Takeovers

Santos 2Q Output Rises 1% as Takeover Campaign Continues

16 Jul 2025, 23:00 UTC

Acquisitions, Mergers, Takeovers

Alimentation Couche-Tard Ends Bid to Buy Seven & I Holdings -- Update

16 Jul 2025, 22:38 UTC

Acquisitions, Mergers, Takeovers

Alimentation Couche-Tard Withdraws Seven & i Acquisition Proposal

16 Jul 2025, 23:44 UTC

Market Talk

Gold Steady; Geopolitical Tensions in Middle East Support -- Market Talk

16 Jul 2025, 23:42 UTC

Market Talk

Nikkei May Fall as Yen Strengthens -- Market Talk

16 Jul 2025, 23:24 UTC

Market Talk

Australian Job Market Data to Shape RBA Calls -- Market Talk

16 Jul 2025, 23:18 UTC

Acquisitions, Mergers, Takeovers

Santos Now Expects 2025 Production of 90 Million-95 Million BOE

16 Jul 2025, 23:18 UTC

Acquisitions, Mergers, Takeovers

Santos Cuts Top End of 2025 Production Guidance

16 Jul 2025, 23:17 UTC

Acquisitions, Mergers, Takeovers

Santos: Production Recovery Underway in Cooper Basin

16 Jul 2025, 23:17 UTC

Acquisitions, Mergers, Takeovers

Santos: Over 200 Wells, Several Upstream Compressors in Cooper Basin Shut In

16 Jul 2025, 23:17 UTC

Acquisitions, Mergers, Takeovers

Santos: Cooper Basin Production Impacted by Floods in 2Q

16 Jul 2025, 23:16 UTC

Acquisitions, Mergers, Takeovers

Santos: Pikka Phase 1 Project in Alasia 89% Complete

16 Jul 2025, 23:16 UTC

Acquisitions, Mergers, Takeovers

Santos Keeps 2025 Major Development Project Capex Guidance Unchanged

16 Jul 2025, 23:13 UTC

Acquisitions, Mergers, Takeovers

Santos Had Gearing of 20.5% at End-June, Excluding Operating Leases

16 Jul 2025, 23:13 UTC

Acquisitions, Mergers, Takeovers

Santos Says Moomba CCS Phase 1 Project Performing to Expectations

16 Jul 2025, 23:12 UTC

Acquisitions, Mergers, Takeovers

Santos Narrows 2025 Unit Production Cost Guidance to US$7.00-US$7.40/BOE

16 Jul 2025, 23:12 UTC

Acquisitions, Mergers, Takeovers

Santos 1H Free Cash Flow From Operations US$1.1 Billion

16 Jul 2025, 23:11 UTC

Acquisitions, Mergers, Takeovers

Santos 2Q Free Cash Flow From Operations US$620 Million

16 Jul 2025, 23:11 UTC

Acquisitions, Mergers, Takeovers

Santos 2Q Oil, Natural Gas Output 22.2 Million BOE

16 Jul 2025, 23:11 UTC

Acquisitions, Mergers, Takeovers

Santos 2Q Oil, Natural Gas Sales Volumes 23.9 Million BOE

16 Jul 2025, 23:11 UTC

Acquisitions, Mergers, Takeovers

Santos 2Q Oil, Natural Gas Sales Volumes Up 3% on 1Q

16 Jul 2025, 23:11 UTC

Acquisitions, Mergers, Takeovers

Santos 2Q Oil, Natural Gas Output Up 1% on 1Q

16 Jul 2025, 22:43 UTC

Market Talk

Alcoa Using High Costs of More Production to Battle Tariff -- Market Talk

16 Jul 2025, 22:35 UTC

Market Talk
Earnings

Global Equities Roundup: Market Talk

16 Jul 2025, 22:35 UTC

Market Talk
Earnings

Replacing Aluminum Imports With U.S. Production Not Seen Feasible -- Market Talk

16 Jul 2025, 22:33 UTC

Market Talk
Earnings

Alcoa Will Continue to Ship Aluminum Outside of the U.S. -- Market Talk

16 Jul 2025, 22:28 UTC

Market Talk
Earnings

Aluminum Price in U.S. Doesn't Offset Tariff Costs, Alcoa says -- Market Talk

16 Jul 2025, 22:22 UTC

Market Talk
Earnings

Market Talk Roundup: Latest on U.S. Politics

16 Jul 2025, 22:22 UTC

Market Talk
Earnings

Alcoa Considers Restart of Idle Capacity at Indiana Smelter -- Market Talk

Peer Comparison

Price change

Clearside Biomedical Inc Forecast

Price Target

By TipRanks

550.6% upside

12 Months Forecast

Average 5.4 USD  550.6%

High 8 USD

Low 3 USD

Based on 5 Wall Street analysts offering 12 month price targets forClearside Biomedical Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

5 ratings

5

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

0.8417 / 0.8939Support & Resistance

Short Term

Neutral Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Weak Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Clearside Biomedical Inc

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.